trending Market Intelligence /marketintelligence/en/news-insights/trending/ylkfg_qxg1-fmydjvg7zya2 content esgSubNav
In This List

Oryzon Genomics adds Synlogic CEO to board

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Oryzon Genomics adds Synlogic CEO to board

Barcelona, Spain-based Oryzon Genomics SA added José Gutiérrez-Ramos to the company's board as an independent director.

Gutiérrez-Ramos is the president and CEO of Synlogic Inc.

Meanwhile, three directors representing Najeti, a private investment fund that owns 20.54% of Oryzon's capital, have resigned from the company's board.

Following the changes, Oryzon's board is now composed of seven directors, with four as independent directors.

Oryzon develops therapies for cancer and neurodegenerative diseases.